Comparative Pharmacology
Head-to-head clinical analysis: ELAPRASE versus PALYNZIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELAPRASE versus PALYNZIQ.
ELAPRASE vs PALYNZIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idursulfase is a recombinant form of iduronate-2-sulfatase, the enzyme deficient in Hunter syndrome (MPS II). It hydrolyzes 2-sulfate groups from the terminal iduronate sulfate glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate, thereby reducing GAG accumulation in tissues.
PALYNZIQ (pegvaliase-pqpz) is a recombinant phenylalanine ammonia lyase conjugated to polyethylene glycol. It converts phenylalanine to trans-cinnamic acid and ammonia, reducing blood phenylalanine levels in patients with phenylketonuria.
0.58 mg/kg IV once weekly administered over 1 hour
2.4 mg subcutaneously once daily.
None Documented
None Documented
Terminal half-life: 6.5–8.5 hours (mean 7.5 h) in pediatric patients; supports weekly IV dosing
Approximately 60–80 hours (terminal half-life); supports weekly dosing regimen.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are reused or excreted
Renal (predominantly as intact pegylated enzyme); less than 5% fecal. No active metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy